Table 2.
Baseline characteristics global cohort and subgroup with simultaneous estimation of TAPSE and PASP
| Variables | Global cohort (n = 684) | Subgroup with echocardiographic parameters (n = 355) | P-value |
|---|---|---|---|
| Age (±SD) | 63.80 (±16.7) | 63.6 (±17.2) | 0.2 |
| Male sex | 296 (43.2%) | 154 (43.4%) | 0.9 |
| Previous thromboembolic disease | 120 (17.5%) | 62 (17.5%) | 1 |
| PE | 32/120 (26.6%) | 17/62 (27.4%) | 0.7 |
| Deep venous thrombosis | 106/120 (88.3%) | 53/62 (85.4%) | 0.1 |
| Arterial hypertension | 383 (55.9%) | 199 (56.1%) | 1 |
| Diabetes | 98 (14.33%) | 55 (15.5%) | 0.6 |
| Former smoking | 188 (27.49%) | 102 (28.7%) | 0.6 |
| Smoking | 76 (11.11%) | 34 (9.4%) | 0.4 |
| Dyslipidaemia | 203 (29.6%) | 113 (31.8%) | 0.5 |
| Atrial fibrillation | 48 (7%) | 32 (9%) | 0.2 |
| Previous ischaemic heart disease | 57 (8.3%) | 35(9.9%) | 0.3 |
| Ambulation | |||
| Without help | 517 (75.58%) | 271 (76.3%) | 0.7 |
| With help | 111 (16.23%) | 55 (15.5%) | |
| Prostrate | 56 (8.19%) | 29 (8.2%) | |
| COPD | 61 (8.9%) | 29 (8.2%) | 0.7 |
| Heart failure | 78 (11.4%) | 45 (12.7%) | 0.5 |
| Hormone therapy | 51 (7.4%) | 22 (6.2%) | 0.4 |
| Ongoing malignancy | 150 (21.9%) | 66 (18.6%) | 0.2 |
| Malignancy in remission | 40 (5.8%) | 19 (5.4%) | 0.8 |
| Chemotherapy | 79 (11.5%) | 40 (11.2%) | 0.8 |
| Stroke | 41 (5.9%) | 18 (5.1%) | 0.6 |
| Procoagulant syndrome | 27 (3.9%) | 15 (4.2%) | 0.8 |
| Obesity | 232 (33.9%) | 116 (32.7%) | 0.6 |
| Major bleeding | 29 (4.26%) | 14 (4%) | 0.8 |
| Autoimmune disease | 35 (5.12%) | 15 (4.2%) | 0.5 |
| Infectious disease | 111 (16.2%) | 40 (11.2%) | 0.03 |
| Recent surgery (3 months) | 164 (23.9%) | 74 (20.7%) | 0.2 |
| Recent hospitalization (3 months) | 230 (33.6%) | 103 (28.9%) | 0.1 |
| Transitional rest >72 h | 186 (29.6%) | 84 (25.8%) | 0.2 |
| Long trip | 42 (6.1%) | 30 (8.5%) | 0.1 |
| Chronic kidney disease | |||
| No dialysis | 44 (6.4%) | 28 (7.9%) | 0.5 |
| Dialysis | 10 (1.4%) | 4 (1.1%) | |
| Previous anticoagulation | 64 (9.3%) | 35 (9.9%) | 0.7 |
| Adequate anticoagulationa | 31/64 (48.4%) | 15/62 (42.9%) | 0.1 |
Sometimes, for a factor or background, the sum of the different categories considered is greater than 100% because there are patients with more than one of them. Qualitative expressed as n (%).
COPD, chronic obstructive pulmonary disease; PE, pulmonary embolism.
a
RIN 2–3 on admission for vitamin K antagonists or with the correct dose of direct oral anticoagulants and low molecular weight heparin.